{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T18:55:52Z","timestamp":1780772152199,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Toll-like receptors (TLR) provide a critical link between innate and adaptive immunity, both important players in atherosclerosis. Since evidence for the role of TLR5 is lacking, we aimed to establish this in the immune axis of atherosclerosis. We assessed the effect of the TLR5-specific ligand Flagellin on macrophage maturation and T-cell polarisation. Next, we generated TLR5<jats:sup>\u2212\/\u2212<\/jats:sup>LDLr<jats:sup>\u2212\/\u2212<\/jats:sup> chimeras to study the effect of hematopoietic TLR5 deficiency on atherosclerosis formation. Flagellin stimulation did not influence wildtype or TLR5<jats:sup>\u2212\/\u2212<\/jats:sup> macrophage maturation. Only in wildtype macrophages, Flagellin exposure increased MCP-1 and IL6 expression. Flagellin alone reduced T-helper 1 proliferation, which was completely overruled in the presence of T-cell receptor activation. <jats:italic>In vivo<\/jats:italic>, hematopoietic TLR5 deficiency attenuated atherosclerotic lesion formation by \u224825% (1030*10<jats:sup>3<\/jats:sup>\u2009\u00b1\u200963*10<jats:sup>3<\/jats:sup> vs. 792*10<jats:sup>3<\/jats:sup>\u2009\u00b1\u200961*10<jats:sup>3<\/jats:sup> \u03bcm<jats:sup>2<\/jats:sup>; p\u2009=\u20090.013) and decreased macrophage area (81.3\u2009\u00b1\u200912.0 vs. 44.2\u2009\u00b1\u20096.6 \u03bcm<jats:sup>2<\/jats:sup>; p\u2009=\u20090.011). In TLR5<jats:sup>\u2212\/\u2212<\/jats:sup> chimeric mice, we observed lower IL6 plasma levels (36.4\u2009\u00b1\u20095.6 vs. 15.1\u2009\u00b1\u20092.2\u2009pg\/mL; p\u2009=\u20090.003), lower (activated) splenic CD4<jats:sup>+<\/jats:sup> T-cell content (32.3\u2009\u00b1\u20092.1 vs. 21.0\u2009\u00b1\u20091.2%; p\u2009=\u20090.0018), accompanied by impaired T-cell proliferative responses. In conclusion, hematopoietic TLR5 deficiency inhibits atherosclerotic lesion formation by attenuated macrophage accumulation and defective T-cell responsiveness.<\/jats:p>","DOI":"10.1038\/srep42688","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T10:09:28Z","timestamp":1487239768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Leukocyte TLR5 deficiency inhibits atherosclerosis by reduced macrophage recruitment and defective T-cell responsiveness"],"prefix":"10.1038","volume":"7","author":[{"given":"Guilielmus H.J.M.","family":"Ellenbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs H.M.","family":"van Puijvelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A.","family":"Anas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Asbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Schoneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"van Santbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Foks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"Doevendans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Pasterkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imo E.","family":"Hoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Kuiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia C.A.","family":"de Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"BFsrep42688_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators*. Global, regional, and national age \u2013 sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117\u2013171 (2014).","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"BFsrep42688_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0002-9149(76)90061-8","volume":"36","author":"WB Kannel","year":"1976","unstructured":"Kannel, W. B., McGee, D. & Gordon, T. A General Cardiovascular Risk Profile: The Framingham Study. Am J Cardiol 36, 46\u201351 (1976).","journal-title":"Am J Cardiol"},{"key":"BFsrep42688_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135\u20131143 (2002).","journal-title":"Circulation"},{"key":"BFsrep42688_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.04.045","volume":"201","author":"YS Hamirani","year":"2008","unstructured":"Hamirani, Y. S. et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 201, 1\u20137 (2008).","journal-title":"Atherosclerosis"},{"key":"BFsrep42688_CR5","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1161\/01.ATV.0000142812.03840.6f","volume":"24","author":"C Weber","year":"2004","unstructured":"Weber, C. Chemokines: Key Regulators of Mononuclear Cell Recruitment in Atherosclerotic Vascular Disease. Arterioscler Thromb Vasc Biol 24, 1997\u20132008 (2004).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFsrep42688_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/13813450601093583","volume":"112","author":"Ea Liehn","year":"2006","unstructured":"Liehn, E. a, Zernecke, A., Postea, O. & Weber, C. Chemokines: inflammatory mediators of atherosclerosis. Arch Physiol Biochem 112, 229\u2013238 (2006).","journal-title":"Arch Physiol Biochem"},{"key":"BFsrep42688_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nri1882","volume":"6","author":"GK Hansson","year":"2006","unstructured":"Hansson, G. K. & Libby, P. The immune response in atherosclerosis : a double-edged sword. Nat Rev Immunol 6, 508\u2013519 (2006).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep42688_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/35100529","volume":"1","author":"R Medzhitov","year":"2001","unstructured":"Medzhitov, R. Toll-like receptors and innate immunity. Nat Rev Immunol 1, 135\u2013145 (2001).","journal-title":"Nat Rev Immunol"},{"key":"BFsrep42688_CR9","doi-asserted-by":"publisher","first-page":"14008","DOI":"10.3390\/ijms140714008","volume":"14","author":"M Falck-hansen","year":"2013","unstructured":"Falck-hansen, M. & Kassiteridi, C. Toll-Like Receptors in Atherosclerosis. Int J Mol Sci 14, 14008\u201314023 (2013).","journal-title":"Int J Mol Sci"},{"key":"BFsrep42688_CR10","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.4049\/jimmunol.1001513","volume":"185","author":"CJ Blohmke","year":"2010","unstructured":"Blohmke, C. J. et al. TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J Immunol 185, 7731\u20138 (2010).","journal-title":"J Immunol"},{"key":"BFsrep42688_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1042\/CS20140444","volume":"129","author":"R Parapanov","year":"2015","unstructured":"Parapanov, R. et al. Toll-like receptor 5 deficiency exacerbates cardiac injury and inflammation induced by myocardial ischaemia-reperfusion in the mouse. Clin Sci 129, 187\u2013198 (2015).","journal-title":"Clin Sci"},{"key":"BFsrep42688_CR12","doi-asserted-by":"crossref","unstructured":"Kim, J., Seo, M., Kim, S. K. & Bae, Y. S. Flagellin-induced NADPH oxidase 4 activation is involved in atherosclerosis. Sci Rep 1\u201316, doi: 10.1038\/srep25437 (2016).","DOI":"10.1038\/srep25437"},{"key":"BFsrep42688_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopha.2016.04.031","volume":"81","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. & Zhang, Y. Pterostilbene, a novel natural plant conduct, inhibits high fat-induced atherosclerosis inflammation via NF-\u03baB signaling pathway in Toll-like receptor 5 (TLR5) deficient mice. Biomed Pharmacother 81, 345\u2013355 (2016).","journal-title":"Biomed Pharmacother"},{"key":"BFsrep42688_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4049\/jimmunol.168.2.554","volume":"168","author":"KA Zarember","year":"2002","unstructured":"Zarember, K. A., Godowski, P. J. & Alerts, E. Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines. J Immunol 168, 554\u2013561 (2002).","journal-title":"J Immunol"},{"key":"BFsrep42688_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.0105-2896.2005.00239.x","volume":"204","author":"IR Rifkin","year":"2005","unstructured":"Rifkin, I. R., Leadbetter, E. A., Busconi, L., Viglianti, G. & Marshak-Rothstein, A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 204, 27\u201342 (2005).","journal-title":"Immunol Rev"},{"key":"BFsrep42688_CR16","doi-asserted-by":"crossref","unstructured":"Monaco, C., Cole, J. E. & Georgiou, E. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm, doi: 10.1155\/2010\/393946 (2010).","DOI":"10.1155\/2010\/393946"},{"key":"BFsrep42688_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1160\/TH11-06-0392","volume":"106","author":"ME Rosenfeld","year":"2011","unstructured":"Rosenfeld, M. E. & Campbell, L. A. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 106, 858\u2013867 (2011).","journal-title":"Thromb Haemost"},{"key":"BFsrep42688_CR18","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1096\/fj.15-272559","volume":"29","author":"A Kassem","year":"2015","unstructured":"Kassem, A., Henning, P., Kindlund, B., Lindholm, C. & Lerner, U. H. TLR5, a novel mediator of innate immunity-induced osteoclastogenesis and bone loss. FASEB J 29, 4449\u20134460 (2015).","journal-title":"FASEB J"},{"key":"BFsrep42688_CR19","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.4049\/jimmunol.167.4.1882","volume":"167","author":"AT Gewirtz","year":"2001","unstructured":"Gewirtz, A. T. et al. Cutting Edge: Bacterial Flagellin Activates Basolaterally Expressed TLR5 to Induce Epithelial Proinflammatory Gene Expression. J Immunol 167, 1882\u20131885 (2001).","journal-title":"J Immunol"},{"key":"BFsrep42688_CR20","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","volume":"168","author":"V Hornung","year":"2002","unstructured":"Hornung, V. et al. Quantitative Expression of Toll-Like Receptor 1 \u2212 10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. J Immunol 168, 4531\u20134537 (2002).","journal-title":"J Immunol"},{"key":"BFsrep42688_CR21","doi-asserted-by":"publisher","first-page":"10229","DOI":"10.1074\/jbc.M100099200","volume":"276","author":"Y Okamura","year":"2001","unstructured":"Okamura, Y. et al. The Extra Domain A of Fibronectin Activates Toll-like Receptor 4*. J Biol Chem 276, 10229\u201310233 (2001).","journal-title":"J Biol Chem"},{"key":"BFsrep42688_CR22","doi-asserted-by":"crossref","unstructured":"Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. 410, 1099\u20131103 (2001).","DOI":"10.1038\/35074106"},{"key":"BFsrep42688_CR23","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/29788","volume":"394","author":"L Boring","year":"1998","unstructured":"Boring, L., Gosling, J., Cleary, M. & Charo, I. F. Decreased lesion formation in CCR2-\/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894\u2013897 (1998).","journal-title":"Nature"},{"key":"BFsrep42688_CR24","doi-asserted-by":"publisher","first-page":"10679","DOI":"10.1073\/pnas.0403249101","volume":"101","author":"KS Michelsen","year":"2004","unstructured":"Michelsen, K. S. et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101, 10679\u201310684 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep42688_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1097-2765(00)80139-2","volume":"2","author":"L Gu","year":"1998","unstructured":"Gu, L. et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2, 275\u2013281 (1998).","journal-title":"Mol Cell"},{"key":"BFsrep42688_CR26","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.4049\/jimmunol.175.12.8051","volume":"175","author":"NK Crellin","year":"2005","unstructured":"Crellin, N. K. et al. Human CD4\u2009+\u2009T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4\u2009+\u2009CD25\u2009+\u2009T regulatory cells. J Immunol 175, 8051\u20138059 (2005).","journal-title":"J Immunol"},{"key":"BFsrep42688_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1139\/y11-071","volume":"89","author":"M Hasu","year":"2011","unstructured":"Hasu, M., Thabet, M., Tam, N. & Whitman, S. C. Specific loss of toll-like receptor 2 on bone marrow derived cells decreases atherosclerosis in LDL receptor null mice. Can J Physiol Pharmacol 89, 737\u201342 (2011).","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep42688","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T20:08:30Z","timestamp":1671826110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep42688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,12]]}},"alternative-id":["BFsrep42688"],"URL":"https:\/\/doi.org\/10.1038\/srep42688","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,16]]},"assertion":[{"value":"22 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42688"}}